ASH 2020 | Impact of MRD on survival in AML
Nicholas Short, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a literature-based meta-analysis of the prognostic impact of measurable residual disease (MRD) on survival in acute myeloid leukemia (AML). The study aimed to clarify the influence of MRD on survival outcomes, as mixed findings have hindered its clinical use. Results showed improved survival was associated with MRD-negativity. Estimated 5-year overall survival (OS) was 68% versus 34% for the MRD-negative and MRD-positive cohort respectively, with a similar disparity seen for disease-free survival (DFS) at 5-years. The superior OS and DFS results were consistent across all AML subgroups and specimen sources. The results of this large-scale analysis indicate MRD status may be a clinically useful endpoint for clinical trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting fees: Takeda Oncology, AstraZeneca
Research funding: Takeda Oncology, Astellas Pharma Inc.
Honoraria: Amgen
